Ollin Biosciences is set to present 20-week data from a randomized clinical trial comparing its drug candidate OLN324 to faricimab, sold under the brand name Vabysmo, in patients with two serious eye conditions. The announcement was reported by Business Wire.
The two conditions covered in the trial are diabetic macular edema and wet age-related macular degeneration. Both involve abnormal blood vessel growth or fluid buildup in the retina that can damage central vision. They are leading causes of vision loss in adults, particularly those over 50 or those living with diabetes.
Faricimab is a biologic therapy approved by the U.S. Food and Drug Administration and considered a standard treatment option for both conditions. Comparing a new drug candidate directly against an existing approved treatment in a head-to-head randomized study is considered a rigorous method for evaluating whether the new therapy offers competitive or superior performance.
The presentation of the 20-week data is described as a milestone in the development of OLN324. Head-to-head trials of this kind are closely watched by clinicians and researchers because they offer a clearer picture of how a new therapy performs relative to established care, rather than against a placebo alone.
Ollin Biosciences has not yet disclosed where the data will be presented, though the announcement referenced an upcoming conference focused on clinical trials in ophthalmology. The company said presentations are forthcoming.
Diabetic macular edema is a complication of diabetic retinopathy, the most common cause of vision loss among working-age adults in the United States. Wet age-related macular degeneration affects millions of older Americans and can cause rapid central vision loss if not treated promptly.
Both conditions currently require regular injections into the eye to manage, and researchers have been working to develop therapies that require fewer treatments over time while maintaining or improving outcomes. Whether OLN324 addresses those goals will be among the questions the full data presentation is expected to address.
